DE602008005643D1 - Parathormon-formulierungen und ihre anwendungen - Google Patents

Parathormon-formulierungen und ihre anwendungen

Info

Publication number
DE602008005643D1
DE602008005643D1 DE602008005643T DE602008005643T DE602008005643D1 DE 602008005643 D1 DE602008005643 D1 DE 602008005643D1 DE 602008005643 T DE602008005643 T DE 602008005643T DE 602008005643 T DE602008005643 T DE 602008005643T DE 602008005643 D1 DE602008005643 D1 DE 602008005643D1
Authority
DE
Germany
Prior art keywords
pth
formulations
parathormone
applications
ionic surfactant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602008005643T
Other languages
English (en)
Inventor
Linderoth Dorte Loer
Hansen Lars Lindegaard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharma AS
Original Assignee
Nycomed Danmark AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Danmark AS filed Critical Nycomed Danmark AS
Publication of DE602008005643D1 publication Critical patent/DE602008005643D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/29Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DE602008005643T 2007-10-26 2008-10-27 Parathormon-formulierungen und ihre anwendungen Active DE602008005643D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99606107P 2007-10-26 2007-10-26
EP07021017A EP2052736A1 (de) 2007-10-26 2007-10-26 Parathyroidhormon-Formulierungen und ihre Verwendungen
PCT/EP2008/009069 WO2009053106A1 (en) 2007-10-26 2008-10-27 Parathyroid hormone formulations and uses thereof

Publications (1)

Publication Number Publication Date
DE602008005643D1 true DE602008005643D1 (de) 2011-04-28

Family

ID=39146901

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602008005643T Active DE602008005643D1 (de) 2007-10-26 2008-10-27 Parathormon-formulierungen und ihre anwendungen

Country Status (15)

Country Link
EP (2) EP2052736A1 (de)
AT (1) ATE501725T1 (de)
CY (1) CY1112106T1 (de)
DE (1) DE602008005643D1 (de)
DK (1) DK2219665T3 (de)
ES (1) ES2363272T3 (de)
HK (1) HK1146465A1 (de)
HR (1) HRP20110444T1 (de)
MX (1) MX2010004388A (de)
PL (1) PL2219665T3 (de)
PT (1) PT2219665E (de)
RU (1) RU2467762C2 (de)
SI (1) SI2219665T1 (de)
WO (1) WO2009053106A1 (de)
ZA (1) ZA201002812B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3332799A1 (de) * 2011-04-22 2018-06-13 Radius Health, Inc. Verfahren zur arzneimittelverabreichung von pth, pthrp und ähnliche peptide
KR102126484B1 (ko) * 2011-05-18 2020-06-25 메더리스 다이어비티즈, 엘엘씨 개선된 펩티드 제약
US9623087B2 (en) 2011-11-30 2017-04-18 3M Innovative Properties Company Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same
EP2883062B1 (de) * 2012-08-13 2019-07-17 Koninklijke Philips N.V. Verwendung von antioxidantien in verfahren und mitteln zum nachweis von zielmolekülen in einer blutprobe
EP4039253A1 (de) 2015-04-29 2022-08-10 Radius Pharmaceuticals, Inc. Verfahren zur behandlung von krebs
GB201602880D0 (en) 2016-02-18 2016-04-06 Ge Healthcare Uk Ltd Method and composition for biomolecule stabilization
KR20230015517A (ko) 2016-03-01 2023-01-31 아센디스 파마 본 디지즈 에이/에스 Pth 프로드럭
SI3518960T1 (sl) 2016-09-29 2023-11-30 Ascendis Pharma Bone Diseases A/S, Odmerni režim za PTH spojino z nadzorovanim sproščanjem
CA3037447A1 (en) 2016-09-29 2018-04-05 Ascendis Pharma Bone Diseases A/S Pth compounds with low peak-to-trough ratios
EP3565542B1 (de) 2017-01-05 2024-04-10 Radius Pharmaceuticals, Inc. Polymorphe formen von rad1901-2hcl
JP6577683B2 (ja) * 2017-09-22 2019-09-18 旭化成ファーマ株式会社 安定性に優れるテリパラチド含有液状医薬組成物
AU2019297421A1 (en) 2018-07-04 2021-01-28 Radius Pharmaceuticals, Inc. Polymorphic forms of RAD 1901-2HCL
CA3107105A1 (en) * 2018-07-30 2020-02-06 Shire-Nps Pharmaceuticals, Inc. Formulations for improved stability of recombinant human parathyroid hormone
AU2020221491A1 (en) * 2019-02-11 2021-08-05 Ascendis Pharma Bone Diseases A/S Liquid pharmaceutical formulations of PTH conjugates
CN112439054B (zh) * 2019-08-28 2023-05-16 深圳翰宇药业股份有限公司 一种特立帕肽缓释凝胶注射液及其制备方法
CN115279396A (zh) * 2020-03-30 2022-11-01 四川泸州步长生物制药有限公司 人类甲状旁腺激素(pth)的制剂及用于生产其的方法
CN113101275A (zh) * 2021-05-27 2021-07-13 海南通用康力制药有限公司 注射用棓丙酯冻干粉针剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1138345A3 (de) * 1993-09-22 2003-06-04 Hisamitsu Pharmaceutical Co., Inc. Eine Matrix für die Iontophorese
ZA966075B (en) * 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
KR101235507B1 (ko) * 2003-02-28 2013-02-20 추가이 세이야쿠 가부시키가이샤 단백질을 함유하는 안정화 제제
EP1682012A4 (de) * 2003-11-13 2008-09-24 Alza Corp Zusammensetzung und gerät zur transdermalen abgabe
WO2007044375A2 (en) * 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
WO2007044069A2 (en) * 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
US8093207B2 (en) * 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products

Also Published As

Publication number Publication date
ZA201002812B (en) 2011-12-28
ATE501725T1 (de) 2011-04-15
MX2010004388A (es) 2010-08-10
EP2052736A1 (de) 2009-04-29
ES2363272T3 (es) 2011-07-28
RU2010121165A (ru) 2011-12-10
HK1146465A1 (en) 2011-06-10
HRP20110444T1 (hr) 2011-08-31
PL2219665T3 (pl) 2011-11-30
DK2219665T3 (da) 2011-06-27
CY1112106T1 (el) 2015-11-04
RU2467762C2 (ru) 2012-11-27
PT2219665E (pt) 2011-06-29
EP2219665B1 (de) 2011-03-16
SI2219665T1 (sl) 2011-09-30
WO2009053106A1 (en) 2009-04-30
EP2219665A1 (de) 2010-08-25

Similar Documents

Publication Publication Date Title
DE602008005643D1 (de) Parathormon-formulierungen und ihre anwendungen
CY1118360T1 (el) Παρατεταμενης διαρκειας τοπικη αναισθητικη συνθεση η οποια περιεχει saib
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
BR112015023391A2 (pt) formulações compreendendo conjugado droga-anticorpo anti-egfr
CO6311084A2 (es) Combinaciones de compuestos activos que tienen propiedades insecticidas y acaricidas
CU20060153A7 (es) Nueva forma cristalina v de agomelatina, procedimiento para su preparación y composiciones farmacéuticas que las contienen
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
PA8595901A1 (es) "n-arilheterociclos sustituidos, procedimientos para su preparacion, y su empleo como medicamentos
IL193074A0 (en) Stable pharmaceutical formulations of montelukast sodium
BRPI0516830A (pt) composições de droga de liberação sustentada convenientemente implantáveis
EA201001440A1 (ru) Композиция, поглощающая кожный жир
DK1819227T3 (da) Farmaceutisk formulering af decitabin
ECSP099413A (es) COMPUESTOS A BASE DE 4 - fenil - 6 - (2,2,2 - trifluoro - 1 - feniletoxi)pirimidina Y MÉTODOS PARA SU EMPLEO
TR200801336T1 (tr) Kararlılığı artmış zayıf su çöznurluğune sahip ilaçların preparasyonuna yönelik kompozisyonlar ve yöntemler.
AR054581A1 (es) Composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion
HK1113970A1 (en) Formulations for injection of catecholic butanes, including ndga compounds, into animals
UA107582C2 (uk) Таблетований препарат (4'-трифторметилфеніл)аміду (z)-2-ціано-гідроксибут-2-еноєвої кислоти з поліпшеною стійкістю
ECSP066912A (es) Formulaciones de dispersiones sólidas de acetato de bazedoxifeno
DK2344130T3 (da) Farmaceutiske topiske sammensætninger
CR9114A (es) 2-alcoxi-3,4,5-trihydroxi-alquimidas, su preparacion composicones que las contienen y su utilizacion
UY28917A1 (es) Derivados de tetrahidroisoquinolilsulfonamidas composiciones farmaceuticas y su uso terapeutico
TN2011000261A1 (en) Octreotide depot formulation with constantly high exposure levels
UY29999A1 (es) "n-pirazinil-fenilsulfonamidas, procedimientos y compuestos intemedios utilizados en su preparacion, composiciones farmaceuticas que las contienen y aplicaciones"
EA201070378A1 (ru) Фармацевтические составы орлистата
AR035284A1 (es) Formulaciones en combinacion de derivados de propanol-amina sustituidos con arilo, junto con otras sustancias activas y su utilizacion